AR108552A1 - Materiales y métodos para determinar los regímenes óptimos de administración para agentes terapéuticos - Google Patents

Materiales y métodos para determinar los regímenes óptimos de administración para agentes terapéuticos

Info

Publication number
AR108552A1
AR108552A1 ARP170101381A ARP170101381A AR108552A1 AR 108552 A1 AR108552 A1 AR 108552A1 AR P170101381 A ARP170101381 A AR P170101381A AR P170101381 A ARP170101381 A AR P170101381A AR 108552 A1 AR108552 A1 AR 108552A1
Authority
AR
Argentina
Prior art keywords
therapeutic agent
value
cells
rate
il2r
Prior art date
Application number
ARP170101381A
Other languages
English (en)
Spanish (es)
Inventor
Volker Teichgrber
Benjamin Ribba
Hans Peter Grimm
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR108552A1 publication Critical patent/AR108552A1/es

Links

Classifications

    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16CCOMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/50Molecular design, e.g. of drugs
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/50ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Theoretical Computer Science (AREA)
  • Computing Systems (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
ARP170101381A 2016-05-25 2017-05-23 Materiales y métodos para determinar los regímenes óptimos de administración para agentes terapéuticos AR108552A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16171263 2016-05-25

Publications (1)

Publication Number Publication Date
AR108552A1 true AR108552A1 (es) 2018-08-29

Family

ID=56096950

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170101381A AR108552A1 (es) 2016-05-25 2017-05-23 Materiales y métodos para determinar los regímenes óptimos de administración para agentes terapéuticos

Country Status (12)

Country Link
US (1) US20190361018A1 (ko)
EP (1) EP3465494A1 (ko)
JP (1) JP6943885B2 (ko)
KR (1) KR20190015345A (ko)
CN (1) CN109478421B (ko)
AR (1) AR108552A1 (ko)
AU (1) AU2017269764A1 (ko)
BR (1) BR112018074152A8 (ko)
CA (1) CA3025050A1 (ko)
IL (1) IL263073A (ko)
MX (1) MX2018014432A (ko)
WO (1) WO2017202786A1 (ko)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3056630A1 (en) 2017-03-15 2018-09-20 Pandion Therapeutics, Inc. Targeted immunotolerance
CN111010866A (zh) 2017-05-24 2020-04-14 潘迪恩治疗公司 靶向免疫耐受性
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
AU2020279240A1 (en) 2019-05-20 2021-12-23 Pandion Operations, Inc. MAdCAM targeted immunotolerance
EP4048302A1 (en) * 2019-10-25 2022-08-31 Neoleukin Therapeutics, Inc. Methods of administration of il-2 receptor agonists
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10245508A1 (de) * 2002-09-27 2004-04-08 Mcs Micro Carrier Systems Gmbh Medikament-Dosimeter-Kombipackung
US20090123428A1 (en) * 2003-04-21 2009-05-14 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
US20070098685A1 (en) * 2005-01-19 2007-05-03 Brand Stephen J Methods and kits to treat chronic inflammatory immune diseases by administering a proteasome inhibitor and an interleukin 2 receptor agonist
JP2009517186A (ja) * 2005-11-29 2009-04-30 チルドレンズ ホスピタル メディカル センター 薬物選択及び投薬の最適化及び個別化
DE102006028232A1 (de) * 2006-06-20 2007-12-27 Bayer Technology Services Gmbh Vorrichtung und Verfahren zur Berechnung und Bereitstellung einer Medikamentendosis
ES2967617T3 (es) * 2013-12-06 2024-05-03 Bioverativ Therapeutics Inc Herramientas de farmacocinética poblacional y sus usos
EP3193915A1 (en) * 2014-07-21 2017-07-26 Novartis AG Combinations of low, immune enhancing. doses of mtor inhibitors and cars
WO2016025385A1 (en) * 2014-08-11 2016-02-18 Delinia, Inc. Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases

Also Published As

Publication number Publication date
CA3025050A1 (en) 2017-11-30
JP2019530907A (ja) 2019-10-24
US20190361018A1 (en) 2019-11-28
IL263073A (en) 2019-03-31
AU2017269764A1 (en) 2018-12-13
EP3465494A1 (en) 2019-04-10
CN109478421B (zh) 2024-07-09
JP6943885B2 (ja) 2021-10-06
BR112018074152A8 (pt) 2023-01-31
WO2017202786A1 (en) 2017-11-30
CN109478421A (zh) 2019-03-15
BR112018074152A2 (pt) 2019-03-06
MX2018014432A (es) 2019-04-01
KR20190015345A (ko) 2019-02-13

Similar Documents

Publication Publication Date Title
AR108552A1 (es) Materiales y métodos para determinar los regímenes óptimos de administración para agentes terapéuticos
CO2019010698A2 (es) Vacunas de peptidos
CL2018002763A1 (es) Moléculas de unión a bcma y métodos de uso de las mismas.
MX2019005125A (es) Variantes de superficie celular discernibles inmunologicamente para uso en terapia celular.
SA522431672B1 (ar) Cd3 أجسام مضادة للارتباط بـ
MX2019008413A (es) Celulas pluripotentes inmunodiseñadas.
CY1122155T1 (el) Συζευγμενες ενωσεις που περιλαμβανουν αντισωματα τροποποιημενης κυστεϊνης
EA202190295A1 (ru) Т-клетки с химерным антигенным рецептором, происходящие от плюрипотентных стволовых клеток, полученных посредством иммуноинженерии
PH12018502250A1 (en) Cancer immunotherapy by immune activation for immune modulation via globo series antigens
AR109707A1 (es) Generación y uso en inmunoterapia adoptiva de células t de memoria tipo células madre
MX2020006715A (es) Anticuerpos especificos del heterodimero de cd3-delta/epsilon.
WO2020113194A3 (en) Methods for treatment using adoptive cell therapy
BR112017014551A2 (pt) ?anticorpo, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos para tratamento de uma doença, para produção de um anticorpo biespecífico e para detecção da possível ocorrência de reticulação entre células com expressão de cd3 e cd20 em uma amostra derivada de um paciente, uso de um anticorpo biespecífico, e, kit?
MX2019004692A (es) Anticuerpos 4-1bb anti-humano y usos de los mismos.
MX2019015155A (es) Modelo de raton para valorar toxicidades asociadas con inmunoterapias.
ECSP21052194A (es) Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp
WO2008094178A3 (en) Models for vaccine assessment
AR104296A1 (es) Infusión arterial hepática de células car-t
WO2014008206A3 (en) DIAGNOSTIC AND THERAPEUTIC POTENTIAL OF HLA-E MONOSPECIFIC MONOCLONAL IgG ANTIBODIES DIRECTED AGAINST TUMOR CELL SURFACE AND SOLUBLE HLA-E
EA201290759A1 (ru) Антитела
MX2021006393A (es) Metodos para expansion ex vivo de celulas exterminadoras naturales y uso de las mismas.
AR066306A1 (es) Conjunto de partes para el tratamiento del cancer o enfermedades infecciosas. composicion farmaceutica- usos
CR20220329A (es) Anticuerpos anti–mertk y metodos de uso de los mismos
AR084263A1 (es) Anticuerpo dirigido contra una proteina de membrana de celulas dendriticas (bdca-2) (blood dendritic cell antigen)
MX2020008730A (es) Regímenes de dosificación de anticuerpo b7-h4.

Legal Events

Date Code Title Description
FB Suspension of granting procedure